

# Special Issue

## Vaccination against Babesiosis

### Message from the Guest Editor

We wish to publish a Special Issue concerning the state of the art in the field of vaccination against Babesia. We invite submissions in the form of original research papers or review papers on the topic of your choice in this area. Babesia and babesiosis as a widespread disease, with multiple clinical forms found in multiple host–parasite interactions, have been studied from multiple angles, and we hope to reflect this diversity in our Special Issue. This represents an opportunity to create an overview of current research that could be translated in efficient actions to control parasites in the field, both for human and animal populations. As a proposal, and among other potential topics, we suggest papers concerning various host and parasite species, ranging from basic science to operational interventions in the field.

### Guest Editor

Dr. Stéphane Delbecq

Centre de Biologie Structurale, INSERM U1054, CNRS UMR 5048,  
Université de Montpellier, 34090 Montpellier, France

### Deadline for manuscript submissions

closed (7 December 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/104979](https://mdpi.com/si/104979)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).